Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STAT3 | P40763 | 1/20 | 0.51 |
| ▸ | STAT1 | P42224 | 1/20 | 0.51 |
| ▸ | PPARG | P37231 | 1/20 | 0.36 |
| ▸ | PPARA | Q07869 | 1/20 | 0.36 |
| ▸ | HDAC3 | O15379 | 6/20 | 0.33 |
| ▸ | HDAC4 | P56524 | 6/20 | 0.33 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.33 |
| ▸ | HDAC7 | Q8WUI4 | 6/20 | 0.33 |
| ▸ | HDAC2 | Q92769 | 6/20 | 0.33 |
| ▸ | HDAC10 | Q969S8 | 6/20 | 0.33 |
| ▸ | HDAC11 | Q96DB2 | 6/20 | 0.33 |
| ▸ | HDAC8 | Q9BY41 | 6/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 6/20 | 0.33 |
| ▸ | HDAC9 | Q9UKV0 | 6/20 | 0.33 |
| ▸ | HDAC5 | Q9UQL6 | 6/20 | 0.33 |
| ▸ | TERT | O14746 | 2/20 | 0.33 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.33 |
| ▸ | DHFR | P00374 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29883333 | 1.00 | STAT3 (0.51) | STAT3STAT1PPARGPPARAHDAC3 | |
| SCHEMBL584793 | 0.99 | STAT3 (0.52) | STAT3STAT1PPARGPPARAHDAC3 | |
| SCHEMBL14383960 | 0.93 | STAT3 (0.46) | STAT3STAT1PPARGPPARACHEK2 | |
| Exeporfinium SCHEMBL584418 | 0.89 | STAT3 (0.51) | STAT3STAT1TERTCYP1A2CYP19A1 | |
| Hydrochloric Acid SCHEMBL588717 | 0.88 | STAT3 (0.41) | STAT3STAT1PPARGPPARATERT | |
| SCHEMBL12066656 | 0.88 | STAT3 (0.48) | STAT3STAT1PPARGPPARATERT | |
| Exeporfinium SCHEMBL585997 | 0.88 | STAT3 (0.52) | STAT3STAT1TERT | |
| SCHEMBL585139 | 0.87 | STAT3 (0.41) | STAT3STAT1PPARGPPARADHFR | |
| Exeporfinium SCHEMBL5012396 | 0.87 | STAT3 (0.51) | STAT3STAT1TERT | |
| Hydrochloric Acid SCHEMBL29648896 | 0.87 | STAT3 (0.48) | STAT3STAT1TERTCYP1A2CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 29 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2022180380-A1 | COMBINATION OF MUPIROCIN WITH PORPHYRIN-BASED PHOTOSENSITIZERS FOR REDUCING ANTIBIOTIC RESISTANCE EMERGENCE | DESTINY PHARMA PLC (GB) | 2022-09-01 | — | — | WO | claimed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | claimed |
| US-8084602-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (CH) | 2011-12-27 | — | — | US | claimed |
| US-7977474-B2 | Uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2011-07-12 | — | — | US | claimed |
| EP-1897883-A2 | Cationic porphyrin derivatives as antibacterial agents | Destiny Pharma Limited (GB) | 2008-03-12 | — | — | EP | claimed |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | DESTINY PHARMA LIMITED | 2007-12-06 | — | — | US | claimed |
| EP-1578750-B1 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | DESTINY PHARMA LTD (GB) | 2007-11-21 | — | — | EP | claimed |
| US-20070167619-A1 | Novel uses of porphyrin compounds | DESTINY PHARMA LTD. (GB) | 2007-07-19 | — | — | US | claimed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | claimed |
| EP-1768666-A1 | NOVEL USES OF PORPHYRIN COMPOUNDS | Destiny Pharma Limited (GB) | 2007-04-04 | — | — | EP | claimed |
| WO-2006000765-A1 | NOVEL USES | DESTINY PHARMA LIMITED (GB) | 2006-01-05 | — | — | WO | claimed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | claimed |
| WO-2022180380-A1 | COMBINATION OF MUPIROCIN WITH PORPHYRIN-BASED PHOTOSENSITIZERS FOR REDUCING ANTIBIOTIC RESISTANCE EMERGENCE | DESTINY PHARMA PLC (GB) | 2022-09-01 | — | — | WO | disclosed |
| US-9326511-B2 | Methods of inhibiting microbial biofilms | DESTINY PHARMA LIMITED (GB) | 2016-05-03 | — | — | US | disclosed |
| EP-2355816-B1 | PORPHYRIN COMPOUNDS FOR KILLING, INHIBITING OR PREVENTING THE GROWTH OF MICROBIAL BIOFILMS | DESTINY PHARMA LTD (GB) | 2014-05-14 | — | — | EP | disclosed |
| EP-1768666-B1 | NOVEL USES OF PORPHYRIN COMPOUNDS | DESTINY PHARMA LTD (GB) | 2012-02-15 | — | — | EP | disclosed |
| US-7244841-B2 | Porphyrin derivatives and their use in photodynamic therapy | DESTINY PHARMA LIMITED (GB) | 2007-07-17 | — | — | US | disclosed |
| EP-1578750-A2 | CATIONIC PORPHYRIN DERIVATIVES AS ANTIBACTERIAL AGENTS | Destiny Pharma Limited (GB) | 2005-09-28 | — | — | EP | disclosed |
| US-20040143001-A1 | Novel compounds and uses thereof | DESTINY PHARMA LIMITED | 2004-07-22 | — | — | US | disclosed |
| WO-2004056828-A2 | NOVEL COMPOUNDS AND USES THEREOF | DESTINY PHARMA LIMITED (GB) | 2004-07-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167619-A1 | Novel uses of porphyrin compounds | PPOX, ZFX, ZYX | STAT3 529/4885STAT1 176/4885PPARG 1962/4885 |
| US-20040143001-A1 | Novel compounds and uses thereof | PPOX, CYP19A1, XDH | STAT3 2198/4885STAT1 2107/4885PPARG 1083/4885 |
| US-20070281915-A1 | Porphyrin Derivatives and Their Use in Photodynamic Therapy | PPOX, PPIF, TYR | STAT3 2340/4885STAT1 1254/4885PPARG 930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.